Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.57 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709338 | 0.82 | HPGD (0.70) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL20740269 | 0.82 | LMNA (0.68) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL1274911 | 0.82 | LMNA (0.68) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL1274285 | 0.82 | LMNA (0.68) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL4406319 | 0.82 | LMNA (0.68) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL4867580 | 0.82 | LMNA (0.68) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL14761562 | 0.82 | LMNA (0.83) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL11704829 | 0.82 | TRPV1 (0.56) | LMNAHTTALDH1A1KMT2A | |
| SCHEMBL6468546 | 0.81 | RAB9A (0.68) | LMNAHTTHPGDALDH1A1RAB9A | |
| SCHEMBL18415459 | 0.81 | LMNA (0.66) | LMNAHTTHPGDALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0098743-B1 | PHENYL ALPHA-ACYLOXYACETAMIDE DERIVATES AND THEIR THERAPEUTIC USE | Yu, Ruey J., Dr. (US) | 1988-09-28 | — | — | EP | claimed |
| EP-2755985-B1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-2943495-B1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2016-12-28 | — | — | EP | disclosed |
| EP-2943495-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | Savira Pharmaceuticals GmbH (AT) | 2015-11-18 | — | — | EP | disclosed |
| US-9045486-B2 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | SAVIRA PHARMACEUTICALS GMBH (AT) | 2015-06-02 | — | — | US | disclosed |
| US-8951985-B2 | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| EP-2755985-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX Pharmaceuticals, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2014108406-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | SAVIRA PHARMACEUTICALS GMBH (AT) | 2014-07-10 | — | — | US | disclosed |
| CN-103906759-A | Compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS INC | 2014-07-02 | — | — | CN | disclosed |
| WO-2013039855-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013039855-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| US-20130064793-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| EP-1973906-A1 | HYDROXYDIHYDROPYRIDOPY RAZINE-1,8-DIONES AND METHODS FOR INHIBITING HIV INTEGRASE | Virochem Pharma Inc. (CA) | 2008-10-01 | — | — | EP | disclosed |
| EP-1906971-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2008-04-09 | — | — | EP | disclosed |
| US-20080076740-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006066414-A1 | HYDROXYDIHYDROPYRIDOPY RAZINE-1,8-DIONES AND METHODS FOR INHIBITING HIV INTEGRASE | VIROCHEM PHARMA INC. (CA) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064793-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, PYGL, EIF2AK2 | LMNA 1839/4885HTT 2175/4885HPGD 1974/4885 |
| US-20140194431-A1 | PYRIMIDONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | TPMT, XDH, DPYD | LMNA 3297/4885HTT 2572/4885HPGD 900/4885 |
| US-20080076740-A1 | Antiviral compounds | EIF2AK2, MAVS, ITPA | LMNA 2219/4885HTT 2589/4885HPGD 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.